Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

294.49 -0.73 (-0.25%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward. 
Via InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
Via Benzinga
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings
Legal battle unfolds as United Therapeutics challenges FDA's handling of Liquidia's drug approval process. Explore the implications on PH-ILD, potential 30-month stay, and recent financial... 
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Earnings Outlook For United Therapeutics
Via Benzinga
United Therapeutics: A Strong Quarter But What About 2024?
United Therapeutics had strong Tyvaso sales but it highlights the investor debate heading into 2024. 
Via Talk Markets
What 4 Analyst Ratings Have To Say About United Therapeutics
Via Benzinga
United Therapeutics's Return On Capital Employed Insights
Via Benzinga
The Latest Analyst Ratings for United Therapeutics
Via Benzinga
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 
Via Benzinga
Topics Intellectual Property
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions. 
Via InvestorPlace
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?
Liquidia Corp (NASDAQ: LQDA) stock jumped after a win in a pat 
Via Benzinga
Why United Therapeutics Shares Are Falling Today
United Therapeutics Corporation's (NASDAQ: UTHR) Q1 revenues grew 10% Y/Y to $506.9 million, missing the  
Via Benzinga
Recap: United Therapeutics Q1 Earnings
Via Benzinga
Analyst Expectations for United Therapeutics's Future
Via Benzinga
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Flying Car Stocks: What a Devastating Short Report Means for EHang
Hindenburg raised red flags for flying car stocks after releasing a short report on EH stock. Here's what investors should watch. 
Via InvestorPlace
EH Stock Alert: Hindenburg Slams EHang in New Short Report
EH stock is falling back to earth after Hindenburg Research issued a short report on the electric vertical take-off and landing (eVTOL) firm. 
Via InvestorPlace
Health Care Company United Therapeutics Announces Acquisition of Miromatrix Medical
Via Benzinga
Why Is Life Sciences Company Miromatrix Medical Stock Trading Higher Today?
United Therapeutics Corporation (NASDAQ: UTHR) has agreed to acquire Miromatrix Medical Inc (NASDAQ: MIRO) for $3.25 per share in cash (an aggregate of approximately $91 million). 
Via Benzinga
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
Why Is Miromatrix Medical (MIRO) Stock Up 235% Today?
Miromatrix Medical stock is rocketing higher on Monday after the company reached an acquisition agreement with United Therapeutics for MIRO. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! 
Via InvestorPlace
Bullet Proof Your Portfolio: 3 Must-Have Defensive Stocks for 2023
Defensive stocks have always been the go-to investments for those looking to protect their long-term portfolio and weather downturns. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names
These are the best biotech stocks that investors can invest in. That's because they are sector leaders that can make you a millionaire. 
Via InvestorPlace
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.